References
- Ganther-Urmie J, Nair K, Valuck R, McCollum M, Lewis S, Turpin R. Consumer attitudes and factors related to prescription switching decisions in multitier co-payment drug benefit plans. Am. J. Manag. Care10, 201–208 (2004).
- Huskamp H, Keating N. The new Medicare drug benefit: formularies and their potential effects on access to medications. J. Gen. Int. Med.20, 662–665 (2005).
- Formulary “negative” change requests unexpectedly increase in early 2007. The Pink Sheet Daily, May 11 (2007).
- Institute of Medicine, Committee on Quality of Health Care. In: Crossing the Quality Chasm: a New Health System for the 21st Century. National Academies Press, DC, USA (2001).
- McClellan M. Drug safety reform at the FDA – pendulum swing or systematic improvement? N. Engl. J. Med.356, 1700–1702 (2007).
- United States Pharmacopeia USP-DI. Volume I: Drug Information for the Health Care Professional (23rd Edition). Thomson, CO, USA (2006).
- Martindale: the Extra Pharmacopeia (31st Edition). Reynolds J (Ed.). Royal Pharmaceutical Society, London, UK (1996).
- Bowman J, Rousseau A, Silk D, Harrison C. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006. Health Affairs25(5), 1240–1248 (2006).
- Hamel M, Epstein A. Prior-authorization programs for controlling drug spending. N. Engl. J. Med.351, 2156–2158 (2004).
- Representative Pete Stark considering making Medicare’s protected drug classes permanent. The Pink Sheet Daily69(27), July 2 (2007).
- Wertheimer A, Levy R, O’Connor T. Too many drugs? The clinical and economic value of incremental innovations. In: Investing in Health: the Social and Economic Bnefits of Health Care Innovation. Farquhar I, Summers K, Sorkin A (Eds). Elsevier, Amsterdam, The Netherlands, 77–118 (2001).
Websites
- Medicare Primer. Kaiser Family Foundation. www.kff.org/medicare/upload/7615.pdf (Accessed March 19, 2007)
- Medicare Fact Sheet (June 2007). Kaiser Family Foundation. www.kff.org/medicare/2052.cfm (Accessed August 23, 2007)
- Prescription drug trends. June 2006. www.kff.org/rxdrugs/upload/3057-05.pdf (Accessed July 31, 2007)
- Hoadley J. The effects of formularies and other cost management tools on access to medications: an analysis of the MMA and the proposed regulations. Kaiser Family Foundation. www.kff.org/medicare/7299.cfm (Accessed May 10, 2007)
- Hoadley J, Hargrave E, Cubanski J, Neuman T. An in-depth examination of formularies and other features of Medicare drug plans. Kaiser Family Foundation. www.kff.org/medicare/7489.cfm (Accessed May 10, 2007)
- Hoadley J, Hargrave E, Merrell K, Cubanski J, Neuman T. Benefit design and formularies of Medicare drug plans: a comparison of 2006 and 2007 offerings: a first look. Kaiser Family Foundation. www.kff.org/medicare/7589.cfm (Accessed January 8, 2008)
- The Medicare bait and switch http://oregonaction.org/pdf/MedicareBaitSwitch.pdf (Accessed March 16, 2007)
- Medicare Modernization Act guidelines – formularies. www.nga.org/files/pdf/0504MMAAPPC.pdf (Accessed March 20, 2007)
- United States Pharmacopeia (2006): Comprehensive listing of drugs in USP model guidelines. www.usp.org/pdf/EN/mmg/finalModelGuidelines2004-12-31.pdf (Accessed May 30, 2006)
- Payment allowance limits for Medicare Part B drugs. www.medicarenhic.com/providers/fees/drugallowlimits_july06.htm (Accessed September 3, 2007)
- Cubanski J, Neuman T, Kates J, Carbaugh A, Han E. The role of Part D for people with HIV/AIDS: coverage and cost of antiretrovirals under Medicare drug plans. www.kff.org/hivaids/7548.cfm (Accessed February 13, 2008)
- Centers for Medicare and Medicaid Services. www.cms.gov